In the New England Journal of Medicine, researchers from the National Cancer Institute say breast cancer risk assessment models don't perform any better when they include common inherited genetic variants linked to the disease. The study's senior investigator, Sholom Wacholder, says the improvement in the risk models wasn't enough to matter to a majority of women. Wacholder and his team combined data from five studies, altogether including 5,590 breast cancer patients and 5,998 healthy women.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.